The US-based biopharmaceutical company has a pipeline of Tarmogen product candidates for infectious disease and multiple cancer indications, including epidermal growth factor receptor over expressing tumors, mutated-Ras mediated cancers, chronic hepatitis C infection, influenza, and targeted ablation of mutational escape. GlobeImmune's products are designed to eliminate or prevent the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies.